Figure 4.

Cumulative incidence of lymphoma-related mortality and NRM after CAR T-cell infusion for patients who received transfusion and those who did not. (A) LRM for RBC transfusion at the early phase. (B) LRM for RBC transfusion at the late phase. (C) LRM for platelets transfusion at the early phase. (D) LRM for platelets transfusion at the late phase. (E) NRM for RBC transfusion at the early phase. (F) NRM for RBC transfusion at the late phase. (G) NRM for platelets transfusion at the early phase. (H) NRM for platelets transfusion at the late phase. LRM, lymphoma-related mortality.